
Veracyte (VCYT) Stock Forecast & Price Target
Veracyte (VCYT) Analyst Ratings
Bulls say
Veracyte is a promising company with a strong presence in the cancer diagnostics industry. Their unique GRID technology sets them apart from competitors and allows for partnerships and research opportunities. With a solid financial position, the company is not only expanding their product portfolio but also making strides towards improving patient outcomes with their MRD and chemotherapy reducing tests.
Bears say
Veracyte is a molecular diagnostics company that has experienced strong revenue growth, but remains highly dependent on just two flagship assets. Although they have recently launched two new products, there are concerns about market saturation in the thyroid testing market and slow adoption of their tests by tenured community urologists. There is potential upside with their new whole-genome MRD test and re-launch of a high-margin breast cancer test, but these may not significantly impact revenue in the near term. Additionally, the company faces competition from larger molecular diagnostics companies and potential pricing pressures.
This aggregate rating is based on analysts' research of Veracyte and is not a guaranteed prediction by Public.com or investment advice.
Veracyte (VCYT) Analyst Forecast & Price Prediction
Start investing in Veracyte (VCYT)
Order type
Buy in
Order amount
Est. shares
0 shares